Kinabalu and Evive Merger Approved; NDF Support Deemed Crucial
NQ Score
0/100
N1 Content Completeness
5
AI Summary (NQ-processed)
Kinabalu's shareholders approved a share swap merger with Evive Biotech, with over 50% voting in favor. The National Development Fund's support was key to the approval. The merger aims to create a 'US-Taiwan biomedical integration platform' by combining local manufacturing with US market access.